Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of novel SIRT3 inhibitors with MLLr leukemia inhibitory potency.

RSC medicinal chemistry·2026
Same author

Lineage tracing from cellular heritage to disease destiny.

Nature genetics·2026
Same author

The heterogeneous treatment effects and joint effects of high-speed rail construction and low-carbon city pilot policy on urban economic resilience.

Fundamental research·2026
Same author

Effects of Three Sweet Potato Varieties on the Development, Survival, and Reproduction of <i>Spodoptera frugiperda</i> Based on an Age-Stage, Two-Sex Life Table Analysis.

Insects·2026
Same author

Mid- to long-term outcomes of different treatment strategies for chronic carotid artery occlusion: a single-center cohort study.

Neurosurgical review·2026
Same author

The Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds.

Biosensors·2026

Related Experiment Video

Updated: Jul 14, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Discovery of Novel PCSK9-LDLR PPI Inhibitors by a Structural Modification Approach.

Huan Zhu1, Zhiqin Zhang2, Lihui Zhang2

  • 1School of Pharmacy, Shandong Second Medical University, Weifang, Shandong, China.

Drug Development Research
|July 13, 2026
PubMed
Summary

New compounds were developed to inhibit proprotein convertase subtilisin/kexin 9 (PCSK9) from degrading the low-density lipoprotein receptor (LDLR). These novel inhibitors show potential for treating hyperlipidemia by restoring LDLR expression and increasing LDL uptake.

Keywords:
LDLLDLRPCSK9PPI inhibitorsmall molecule

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Jul 14, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

  • Medicinal Chemistry
  • Biochemistry
  • Pharmacology

Background:

  • Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of hepatic low-density lipoprotein receptors (LDLR).
  • PCSK9's role in LDLR degradation makes it a therapeutic target for hyperlipidemia.
  • Disrupting the PCSK9-LDLR interaction is a strategy to manage lipid levels.

Purpose of the Study:

  • To design and synthesize novel compounds that inhibit the protein-protein interaction (PPI) between PCSK9 and LDLR.
  • To evaluate the efficacy of these compounds in disrupting PCSK9-LDLR binding and restoring LDLR function.
  • To identify lead compounds for further development as PCSK9-LDLR PPI inhibitors.

Main Methods:

  • Synthesis of 43 compounds based on structural modifications of known PCSK9 inhibitors.
  • In vitro PCSK9-LDLR PPI interfering assays to determine IC50 values.
  • Molecular docking simulations to predict binding modes and interactions.
  • Cell-based assays (HepG2 cells) to assess LDLR expression and LDL uptake.

Main Results:

  • Compounds B7, B23, and B27 demonstrated significant inhibitory potency against PCSK9-LDLR interaction, with IC50 values of 8.86 μM, 3.95 μM, and 5.02 μM, respectively.
  • Molecular docking indicated that hydrophobic interactions are crucial for the binding of compound B27 to PCSK9.
  • Compounds B7, B23, and B27 successfully restored LDLR expression and enhanced LDL uptake in HepG2 cells under PCSK9 influence.

Conclusions:

  • Novel compounds targeting the PCSK9-LDLR PPI have been successfully designed and synthesized.
  • Lead compounds, particularly B27, exhibit promising lipid-lowering potential by inhibiting PCSK9 activity.
  • These findings provide a foundation for the further development of PCSK9-LDLR PPI inhibitors for hyperlipidemia treatment.